CytoDyn (CYDY) Research & Development (2010 - 2024)
CytoDyn's (CYDY) quarterly Research & Development came in at $3.6 million in Q2 2024, up 266.67% YoY from $981000.0 in Q2 2023, and up 453.38% on a QoQ basis from $650000.0 in Q1 2024.
CytoDyn (CYDY) Research & Development (2010 - 2024) Analysis & Trends
CytoDyn (CYDY) has 15 years of Research & Development data on file, last reported at $3.6 million in Q2 2024.
- Quarterly Research & Development rose 266.67% year-over-year to $3.6 million in Q2 2024, while the trailing twelve-month figure through May 2024 was $7.2 million (up 175.08% YoY) and the FY2024 annual result came in at $7.2 million, up 175.08% from the prior year.
- Research & Development improved to $3.6 million in Q2 2024, from $650000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $19.9 million in Q2 2020 to a low of $137000.0 in Q4 2022.
- A 5-year average of $7.0 million and a median of $3.8 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 98.16% — and 2023, when it surged 687.59%.
- Tracing CYDY's Research & Development over 5 years: stood at $16.4 million in 2020, then slumped by 54.72% to $7.4 million in 2021, then plunged by 98.16% to $137000.0 in 2022, then surged by 687.59% to $1.1 million in 2023, then soared by 233.36% to $3.6 million in 2024.
- The last three Research & Development figures came in at $3.6 million (Q2 2024), $650000.0 (Q1 2024), and $1.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2024 | 3.60 Mn |
| Feb 29, 2024 | 650,000.00 |
| Nov 30, 2023 | 1.08 Mn |
| Aug 31, 2023 | 1.91 Mn |
| May 31, 2023 | 981,000.00 |
| Feb 28, 2023 | 938,000.00 |
| Nov 30, 2022 | 137,000.00 |
| Aug 31, 2022 | 576,000.00 |
| May 31, 2022 | 4.01 Mn |
| Feb 28, 2022 | 3.57 Mn |
| Nov 30, 2021 | 7.45 Mn |
| Aug 31, 2021 | 12.02 Mn |
| May 31, 2021 | 9.34 Mn |
| Feb 28, 2021 | 12.32 Mn |
| Nov 30, 2020 | 16.45 Mn |
| Aug 31, 2020 | 15.19 Mn |
| May 31, 2020 | 19.95 Mn |
| Feb 29, 2020 | 15.11 Mn |
| Nov 30, 2019 | 8.53 Mn |
| Aug 31, 2019 | 9.06 Mn |